Disabled people learn how to take charge of their own care

Pathfinders Neuromuscular Alliance are offering a free training programme to people with neuromuscular conditions to help them become confident Independent Employers of their own PAs. It is run with support from Skills for Care and ACAS. It is improving hugely popular with people on Direct Payments, and Pathfinders have reserved up to eight places exclusively for TreatSMA members on the courses, with access code TreatSMA23.

Pathfinders state that there are many options for young people and adults with muscle-weakening conditions to gain independence. One of the most life-changing is the right to use self-directed support to employ personal assistants directly.

They also acknowledge how overwhelming and frustrating it can be; unfortunately, many worry that they don’t have the skills. Typically, the paperwork and legal framework are provided, but there is more to having PAs than just filling in the forms. How can you find the right people? How do you organise them? What might go wrong, and what do you do if it does?”

You can read some press coverage about the courses here: https://hubpublishing.co.uk/disabled-people-learn-how-to-take-charge-of-their-own-care/. Pathfinders want to reach as many people as possible but also want to ensure that some places are held for TreatSMA members.

The live online course will be delivered by people with neuromuscular conditions and is suitable for anyone who is already an Independent Employer, who wants to become one or is approaching transition to adult services. It will run twice: on the 21st & 24th of March 2023 and again on the 3rd & 6th of April 2023.

To use TreatSMA’s places, please direct your members to https://www.eventbrite.com/cc/how-to-be-an-independent-employer-of-your-own-pas-1786239 and give them your exclusive access code (TreatSMA) to enter when booking.

Thank you

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more